TheraCryf Plc
TCF · AIM · Health Care · mcap £3.7m · 0.2p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 09 Oct 26 | Change of Nominated Adviser
TheraCryf plc, the biotech company developing new medicines for addiction and other neuropsychiatric disorders, announces that it has appointed Strand Hanson Limited as its Financial and Nominated Adviser with immediate |
−5.6% | |
| 02 Oct 26 | Australian partner to progress Ox-1 Phase 1 trial
TheraCryf appoints Avance Clinical to support Australian Phase 1 trial preparations for Ox-1 programme. |
+0.0% | |
| 28 Sep 26 | Results | Final Results
FY26 results: Ox-1 programme on track for phase 1 submission, £1.05m fundraising post-period, rejected takeover approach. |
+0.0% |
| 20 Aug 26 | Fundraise | Proposed Placing & Subscription to raise £1.05m
TheraCryf raises £1.05m via placing and subscription at 0.18p per share to fund Orexin-1 programme. |
+0.0% |
| 14 May 26 | Positive Ox-1 tox data in addiction programme
Ox-1 toxicology data shows good tolerability; Phase 1 application expected by end Q3 2026. |
+11.4% | |
| 21 Apr 26 | Investor Webinar
TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces that Dr Huw Jones, Chief Executive Officer and Dr Helen Kuhlman, Chief Operating |
+0.0% | |
| 20 Apr 26 | Successful GMP Manufacture Advances Ox-1 to Clinic
TheraCryf successfully manufactured over 2kg of clinical-grade Ox-1 drug substance to GMP standard, three weeks ahead of schedule. |
+0.0% | |
| 16 Apr 26 | New Manufacturing Process Patent for Ox-1
TheraCryf files new manufacturing process patent for Ox-1 providing potential protection to 2046. |
+6.7% | |
| 14 Apr 26 | Non-Binding Proposal to Acquire TheraCryf’s Assets
Board rejects non-binding proposal to acquire lead neuropsychiatry assets, citing undervaluation. |
+15.4% | |
| 23 Mar 26 | Ox-1 Programme Advances to Final Toxicology Study
Lead Ox-1 programme completes dose range finding studies, progresses to final toxicology studies before human trials. |
+0.0% | |
| 26 Jan 26 | Ox-1 Addiction Programme Update
Canadian patent granted for Ox-1 addiction programme; preclinical safety studies progressing towards IND readiness in 2026. |
+0.0% | |
| 05 Jan 26 | Key Ox-1 milestone & notice of investor webinar
Ox-1 addiction programme advances closer to clinical readiness on achievement of key milestone |
+0.0% | |
| 18 Dec 25 | Potential of Preclinical Program in Mental Fatigue
TheraCryf highlights potential of DAT dopamine modulator programme targeting mental and cognitive fatigue. |
−4.8% | |
| 03 Dec 25 | Results | Half-year Results
Half-year results show Ox-1 addiction programme on track for regulatory submission in Q4 2026, cash position strengthened to £3.5m. |
+11.6% |
| 26 Nov 25 | Marking Addiction Awareness Week
TheraCryf supporting Addiction Awareness Week; Ox-1 programme progressing on budget and ahead of schedule. |
+0.0% | |
| 03 Nov 25 | Ox-1 Programme Achieves Manufacturing Milestone
TheraCryf achieves 0.5kg scale-up of Ox-1 compound ahead of schedule; initiates human-grade manufacturing. |
+0.0% | |
| 10 Oct 25 | World Mental Health Day & Q4 Conference Schedule
TheraCryf notes World Mental Health Day and announces Q4 2025 conference schedule. |
+0.0% |
Company filings. Not investment advice.